DrugRisk Update: Pradaxa Maker Pays for Study to Dispute Risks

Los Angeles, CA (PRWEB) February 26, 2013

The prescription drug resource center DrugRisk.com is alerting patients taking the popular blood thinner Pradaxa of updated information added to the site showing the maker of Pradaxa, Boehringer Ingelheim, has funded a study which disputes prior warnings over bleeding risks.

DrugRisks mission is to improve the patient safety by providing the latest drug warnings, recalls, studies and litigation news. In the case of research, it is important for patients to know whether it is independent or funded by drug makers with a financial stake in the outcome, explains DrugRisk representative Ryan Mayer.

The resource center contains information from health organizations showing experts have differing opinions about the safety of Pradaxa. The FDA recently updated an advisory to indicate the drug carries the same risks as warfarin.* However, the American College of Cardiology has warned Pradaxa can significantly increase the risk of bleeding complications compared to warfarin.**

DrugRisk has also obtained a recent study from the Institute for Safe Medication Practices which again ranks blood thinners like Pradaxa among the most dangerous drugs. In reviewing nearly 18,000 adverse events reported to the FDA, the institute found those patients with bleeding from Pradaxa are nearly 5 times as likely to die than those with bleeding from warfarin.***

Due to the number of patients filing a Pradaxa lawsuit over bleeding side effects, the cases have been consolidated to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Now, DrugRisk has learned that the maker of Pradaxa, Boehringer Ingelheim, has paid for a new study at McMaster University in Ontario, Canada, which followed only 2,800 patients, but concluded Pradaxa is safer than warfarin and has less-severe results for those that do experience bleeding.****

Patients are urged to speak with their doctor about the reliability of the studies.

Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

See the original post here:
DrugRisk Update: Pradaxa Maker Pays for Study to Dispute Risks